Saturday 17 October 2026
Export TTOO’s income statement to Excel — free account
T2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022. Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow TTOO
| Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 2 | 5 | 5 | 2 | 6 | 3 | 3 |
P/S ratio |
1.96 | 0.37 | 0.06 | 0.17 | 0.13 | 0.23 | 0.61 | 0.67 |
Altman Z-Score |
(28.92) | (26.06) | (12.14) | (8.29) | (25.97) | (8.95) | (10.08) | (4.10) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(70.64) | (60.34) | (26.84) | (17.19) | (65.50) | (20.12) | (23.28) | (5.61) |
P/Operating CF |
(1.50) | (0.79) | (0.17) | (0.34) | (0.11) | (0.25) | (0.26) | (0.26) |
Beneish M-Score |
— | (2.75) | (4.19) | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.35 | 0.00 | 0.21 | 2.12 | 0.07 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.35 | 0.00 | 0.21 | 2.12 | 0.07 |
EV/Sales |
6.75 | 2.13 | 0.61 | 0.33 | (0.97) | (4.56) | (7.98) | (7.47) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 1.12 | 0.73 | 0.63 |
EV/Operating CF |
(1.01) | (0.94) | (0.44) | (0.14) | 0.18 | 1.19 | 0.78 | 0.66 |
EV/FCF |
(1.00) | (0.93) | (0.44) | (0.14) | 0.18 | 1.18 | 0.74 | 0.59 |
Quick Ratio |
0.30 | 1.23 | 3.20 | 4.83 | 0.23 | 1.01 | 0.82 | 7.47 |
Current Ratio |
0.45 | 1.91 | 3.80 | 5.47 | 0.31 | 1.08 | 0.86 | 7.63 |
Net Debt/EBITDA |
0.32 | (0.73) | (0.39) | (0.08) | 0.19 | 1.18 | 0.79 | 0.68 |
Debt/Assets |
0.00% | 144.64% | 78.94% | 57.20% | 6.58% | 0.77% | 3.17% | 44.99% |
Debt/Equity |
0.00 | (1.25) | (3.70) | 5.18 | (0.06) | 0.04 | 1.30 | 1.02 |
Asset Turnover |
0.21 | 0.47 | 0.40 | 0.34 | 0.18 | 0.18 | 0.06 | 0.05 |
Operating CF/Net income |
0.96 | 0.81 | 0.79 | 0.92 | 0.77 | 0.78 | 0.76 | 0.85 |
Capex/Depreciation |
(0.22) | (0.32) | (0.17) | (0.25) | (0.21) | (0.24) | (0.84) | (2.41) |
Interest Coverage |
(9.30) | (9.07) | (5.66) | (7.49) | (7.08) | (6.75) | (6.05) | (12.42) |
| 147.96% | 237.20% | 2,357.72% | 370.25% | 521.76% | (803.85%) | (306.94%) | (127.04%) | |
| (144.89%) | (131.41%) | (70.54%) | (87.01%) | (127.17%) | (85.85%) | (86.45%) | (62.14%) | |
ROIC |
0.00% | 0.00% | (1,015.05%) | (219.57%) | 0.00% | 0.00% | 0.00% | (517.39%) |
Return on Tangible Assets |
170.88% | (452.87%) | (131.73%) | (98.41%) | 164.67% | (439.99%) | (2,447.20%) | (69.25%) |
Average Days of Receivables |
72.06 | 35.40 | 66.79 | 102.66 | 123.71 | 62.08 | 36.53 | 29.25 |
Research and Development Expense of Revenue |
196.76% | 115.29% | 77.70% | 88.87% | 195.87% | 137.99% | 508.64% | 588.46% |
Selling, General and Administrative Expense of Revenue |
345.20% | 137.30% | 101.67% | 121.86% | 327.58% | 244.73% | 487.72% | 590.12% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
60.49% | 29.11% | 25.27% | 21.58% | 65.48% | 94.26% | 102.66% | 118.82% |
Graham Net Nets |
(2.67) | (6.69) | (17.70) | (5.56) | (40.95) | 1.51 | (3.25) | 9.27 |
Graham Number |
68.78 | 4,631.10 | 3,700.57 | 0.00 | 23,377.53 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(361.83%) | (766.19%) | (2,905.85%) | (1,854.84%) | (5,555.56%) | (2,126.25%) | (2,188.73%) | (2,017.21%) |
Free Cash Flow Yield |
(342.26%) | (624.61%) | (2,396.20%) | (1,460.74%) | (4,331.92%) | (1,670.60%) | (1,770.39%) | (1,909.44%) |
Revenue per Share |
2.76 | 437.35 | 882.33 | 746.09 | 915.93 | 1,296.30 | 729.06 | 784.62 |
Operating CF per Share |
(18.44) | (992.73) | (1,222.45) | (1,778.40) | (4,984.73) | (4,955.31) | (7,455.94) | (8,931.15) |
Capex per Share |
(0.07) | (6.65) | (14.47) | (32.92) | (83.63) | (73.21) | (386.87) | (1,055.19) |
Free Cash Flow per Share |
(18.52) | (999.37) | (1,236.92) | (1,811.32) | (5,068.35) | (5,028.52) | (7,842.81) | (9,986.35) |
Cash per Share |
6.01 | 202.53 | 1,013.87 | 1,736.17 | 1,212.42 | 6,272.22 | 6,531.09 | 14,132.31 |
Shareholders Equity per Share |
(10.74) | (777.55) | (405.75) | 359.09 | (3,736.81) | 1,405.80 | 209.38 | 7,565.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Book value per Share |
(10.74) | (777.55) | (405.75) | 359.09 | (3,736.81) | 1,405.80 | 209.38 | 7,565.00 |
Free Cash Flow |
(48.33) | (50.97) | (39.33) | (44.01) | (46.12) | (40.73) | (50.19) | (51.93) |
Working Capital |
(30.96) | 9.23 | 32.71 | 43.78 | (41.68) | 4.31 | (7.46) | 65.55 |
Capital Expenditures |
(0.19) | (0.34) | (0.46) | (0.80) | (0.76) | (0.59) | (2.48) | (5.49) |
Net Current Asset Value |
(37.64) | (54.62) | (29.05) | (16.77) | (43.60) | 3.69 | (9.20) | 25.21 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 1.06 | 0.69 | 0.60 |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.04 | 0.09 | 0.06 | 0.53 | 1.34 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.52 | 0.23 | 0.58 | 0.86 | 0.62 | 0.33 | 0.29 | 0.17 |
Cash ROIC |
391.41% | (250.77%) | (58.60%) | (45.78%) | 218.60% | (64.98%) | (111.85%) | (33.91%) |
Accounts Receivable Turnover |
4.02 | 6.11 | 5.48 | 4.58 | 3.62 | 9.32 | 11.75 | 11.72 |
Accounts Payable Turnover |
10.88 | 10.18 | 8.47 | 7.32 | 7.46 | 22.13 | 14.94 | 6.28 |
Inventory Turnover |
3.38 | 5.13 | 5.49 | 5.88 | 5.34 | 7.66 | 11.20 | 9.25 |
Average Days of Payables |
36.28 | 22.52 | 49.93 | 35.30 | 81.72 | 17.63 | 19.66 | 51.10 |
Days of Inventory on Hand |
114.49 | 74.44 | 68.92 | 62.37 | 78.37 | 63.43 | 40.78 | 42.65 |
Average Receivables |
1.79 | 3.65 | 5.12 | 3.96 | 2.31 | 1.13 | 0.40 | 0.35 |
Average Payables |
1.41 | 2.06 | 2.45 | 2.91 | 2.25 | 0.70 | 0.81 | 1.10 |
Average Inventory |
4.55 | 4.10 | 3.77 | 3.62 | 3.14 | 2.01 | 1.07 | 0.74 |
Average Assets |
34.56 | 47.43 | 69.81 | 53.78 | 46.40 | 59.59 | 72.21 | 88.20 |
Average Common Equity |
(33.85) | (26.28) | (2.09) | (12.64) | (11.31) | 6.36 | 20.34 | 43.14 |
Columns are period end dates